Collaboration and license agreements - Schedule of financial information related to collaboration and license agreements (Details) - USD ($) $ in Thousands	Sep. 30, 2024	Dec. 31, 2023
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Accounts Receivable	$ 10,341	$ 11,799
Deferred revenue, current	20,769	15,471
Deferred revenue, net of current	28,648	21,814
Deferred revenue, total	49,417	37,285
MKDG Agreement
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Accounts Receivable	1,572
Deferred revenue, current	4,770
Deferred revenue, net of current	9,652
Deferred revenue, total	14,422
Merck Agreement
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Accounts Receivable	0	10,000
Deferred revenue, current	6,569	8,000
Deferred revenue, net of current	0	2,000
Deferred revenue, total	6,569	10,000
Betta Agreements
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Accounts Receivable	769	1,799
Deferred revenue, current	4,203	4,000
Deferred revenue, net of current	11,107	8,000
Deferred revenue, total	15,310	12,000
Roche Agreement
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Accounts Receivable	0	0
Deferred revenue, current	5,227	2,667
Deferred revenue, net of current	7,889	11,814
Deferred revenue, total	13,116	14,481
Biogen Agreement
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Accounts Receivable	8,000	0
Deferred revenue, current	0	804
Deferred revenue, net of current	0	0
Deferred revenue, total	$ 0	$ 804